Crescendo Biologics has raised GBP4.5m in a seed-funding led by Sofinnova Partners, to advance the development of its fragment antibody technology platforms. The company claims that the technology
Raptor Pharmaceutical (Raptor) has reported positive findings from the completed treatment phase of its open-label phase 2a clinical trial of delayed-release cysteamine bitartrate (DR Cysteamine), in adolescent patients
Germany-based, Merck KgaA is going to launch Parteck ODT, a directly compressible excipient developed for fast-acting orally disintegrating tablets, at the CPhI Worldwide in Madrid. According to the
Depomed has reported top-line results from the BREEZE 1 and 2 phase 3 clinical trials evaluating the safety and efficacy of Serada. Its an investigational non-hormonal extended release
NOXXON Pharma (NOXXON) has reported the successful completion of the first phase I trial with its anti-inflammatory Spiegelmer NOX-E36. This drug candidate will be developed for the treatment
In response to the launch of its branded generic pharmaceutical products in India, SOHM has received orders from its distributors in Northern India for antibiotics, anti-cold, anti-asthmatic, and
Orion Genomics has entered into a multi-year collaboration and license agreement with the molecular diagnostics unit of Novartis. As per the agreement, the parties seek to discover novel
Celator Pharmaceuticals has completed enrollment in its phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, versus conventional cytarabine and daunorubicin therapy. It was conducted
MDRNA has presented new in vivo data demonstrating continued progress in the advancement of its oncology program. The company reported that MDRNA’s UsiRNAs, delivered by its DiLA2 platform,
ImmuneRegen BioSciences (ImmuneRegen), a wholly-owned subsidiary of IR Biosciences, has initiated a study utilising the highly pathogenic H5N1-Clade 2 virus to test the efficacy of its lead anti-influenza
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.